Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eltrapuldencel-T
- Development stage
- Phase 1
- Lead developer
- Lisata Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Subcutaneous
01
Overview
Eltrapuldencel-T is an autologous dendritic cell-based immunotherapy developed for the treatment of malignant melanoma. The therapy involves harvesting a patient's own dendritic cells and loading them *ex vivo* with antigens derived from self-renewing, proliferating, irradiated autologous tumor cells. These antigen-loaded dendritic cells are then administered to the patient in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate an immune response against tumor-associated antigens unique to the individual's cancer. The mechanism of action is immunostimulation via presentation of tumor antigens by dendritic cells, leading to activation of T lymphocytes and induction of anti-tumor immunity. Eltrapuldencel-T was granted orphan drug status for malignant melanoma and received special protocol assessment (SPA) and fast track designation from the FDA. Development was discontinued after termination of a phase III trial in late-stage malignant melanoma[1][2][3][4].
- Other names
- Autologous stem cell therapy - California Stem CellCancer stem cell - California Stem CellMalignant melanoma stem cell therapy - NeoStem OncologyMelapuldencel-T
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on Eltrapuldencel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eltrapuldencel-T.